Global Emergency Contraceptives Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Emergency Contraceptives Market Research Report 2024
The emergency contraceptives market refers to the industry involved in the production, distribution, and sale of medications and products used for emergency contraception. Emergency contraceptives, also known as "morning-after pills," are designed to prevent pregnancy after unprotected intercourse or contraceptive failure.
According to Mr Accuracy reports new survey, global Emergency Contraceptives market is projected to reach US$ 936.7 million in 2029, increasing from US$ 568 million in 2022, with the CAGR of 7.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Emergency Contraceptives market research.
The emergency contraceptives market is a segment within the broader contraceptive industry. It focuses on providing women with safe and effective options for emergency contraception when regular contraceptive methods have failed, were not used, or in cases of sexual assault.
The emergency contraceptives market is influenced by factors such as changing societal norms, increasing awareness of contraception options, rising demand for reproductive healthcare services, and initiatives to reduce unintended pregnancies. Additionally, the market is driven by advancements in emergency contraceptive formulations and the expansion of distribution channels.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Emergency Contraceptives market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Genetics
Teva Pharmaceutical
Uniprix
Gavis Pharmaceuticals
HRA Pharma
Mankind Pharma
Segment by Type
Combined Estrogen and Progestin Pills
Progestin-Only (As Levonorgestrel) Pills
Antiprogestin (As Mifepristone) Pills
Ulipristal Acetate Pills
Hospital pharmacies
Retail pharmacies
Online pharmacies
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Emergency Contraceptives report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Emergency Contraceptives market is projected to reach US$ 936.7 million in 2029, increasing from US$ 568 million in 2022, with the CAGR of 7.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Emergency Contraceptives market research.
The emergency contraceptives market is a segment within the broader contraceptive industry. It focuses on providing women with safe and effective options for emergency contraception when regular contraceptive methods have failed, were not used, or in cases of sexual assault.
The emergency contraceptives market is influenced by factors such as changing societal norms, increasing awareness of contraception options, rising demand for reproductive healthcare services, and initiatives to reduce unintended pregnancies. Additionally, the market is driven by advancements in emergency contraceptive formulations and the expansion of distribution channels.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Emergency Contraceptives market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Genetics
Teva Pharmaceutical
Uniprix
Gavis Pharmaceuticals
HRA Pharma
Mankind Pharma
Segment by Type
Combined Estrogen and Progestin Pills
Progestin-Only (As Levonorgestrel) Pills
Antiprogestin (As Mifepristone) Pills
Ulipristal Acetate Pills
Segment by Application
Hospital pharmacies
Retail pharmacies
Online pharmacies
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Emergency Contraceptives report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source